持田製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4534/E00947 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2022/06/10 | 日証協 | 148,904株 | +2.62% | 25,091株 | -86.48% | 106,488株 | -3.54% | 12,800株 | -70.57% |
2022/06/03 | 日証協 | 145,107株 | -38.75% | 185,630株 | -66.52% | 110,391株 | -47.38% | 43,500株 | -24.22% |
2022/05/27 | 日証協 | 236,904株 | +24.28% | 554,451株 | +69.85% | 209,788株 | +28.24% | 57,400株 | -31.7% |
2022/05/20 | 日証協 | 190,624株 | +53.39% | 326,434株 | +1185.02% | 163,588株 | +55.43% | 84,041株 | +517.95% |
2022/05/13 | 日証協 | 124,271株 | +6.7% | 25,403株 | -11.62% | 105,247株 | +10.85% | 13,600株 | +156.6% |
2022/05/06 | 日証協 | 116,471株 | -0.64% | 28,743株 | -74.65% | 94,947株 | -12.77% | 5,300株 | -74.02% |
2022/04/28 | 日証協 | 117,227株 | +45.57% | 113,367株 | +99.72% | 108,847株 | +5.83% | 20,400株 | -37.23% |
2022/04/22 | 日証協 | 80,527株 | +11.96% | 56,764株 | +173.1% | 102,850株 | +13.84% | 32,500株 | +85.71% |
2022/04/15 | 日証協 | 71,927株 | +37.72% | 20,785株 | -71.29% | 90,350株 | -2.58% | 17,500株 | -20.09% |
2022/04/08 | 日証協 | 52,227株 | +569.58% | 72,400株 | +143.03% | 92,745株 | -14.53% | 21,901株 | -42.02% |
2022/04/01 | 日証協 | 7,800株 | -87.74% | 29,790株 | -63.42% | 108,518株 | -29.98% | 37,771株 | +285.42% |
2022/03/25 | 日証協 | 63,621株 | -13.44% | 81,428株 | -20.88% | 154,985株 | -8.5% | 9,800株 | -87.35% |
2022/03/18 | 日証協 | 73,500株 | -30.66% | 102,913株 | -20.1% | 169,385株 | +11.57% | 77,461株 | +31% |
2022/03/11 | 日証協 | 106,000株 | +5.58% | 128,795株 | +15.41% | 151,824株 | -2.04% | 59,129株 | +215.41% |
2022/03/04 | 日証協 | 100,400株 | -7.28% | 111,600株 | +84.77% | 154,990株 | -4.63% | 18,747株 | +95.26% |
2022/02/25 | 日証協 | 108,280株 | -20.12% | 60,399株 | -51% | 162,516株 | -3.27% | 9,601株 | -72.65% |
2022/02/18 | 日証協 | 135,559株 | +11.02% | 123,254株 | +75.95% | 168,018株 | +13.56% | 35,100株 | +12.14% |
2022/02/10 | 日証協 | 122,105株 | -2.86% | 70,051株 | -44% | 147,961株 | -0.8% | 31,300株 | -45.84% |
2022/02/04 | 日証協 | 125,696株 | +10.94% | 125,096株 | +41.67% | 149,156株 | +32.98% | 57,790株 | +93.28% |
※株式分割は考慮していませんのでご注意ください。
Page Top